These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 8686186)

  • 21. [5-Aminosalicylic acid in treatment of non-specific enteritis].
    Adrych K; Zaucha JM; Kryszewski A
    Wiad Lek; 1993 Nov; 46(21-22):833-6. PubMed ID: 7817574
    [No Abstract]   [Full Text] [Related]  

  • 22. [Salicylic derivatives in the clinical treatment of inflammatory bowel disease: new perspectives].
    Damião AO; Sipahi AM
    Rev Hosp Clin Fac Med Sao Paulo; 1989; 44(5):271-8. PubMed ID: 2576896
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [New salicylic acid derivatives in the treatment of inflammatory intestinal diseases].
    Kovács A
    Orv Hetil; 1991 Jun; 132(24):1317-21. PubMed ID: 1677465
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pancreatitis induced by mesalamine.
    Erdkamp F; Houben M; Ackerman E; Breed W; van Spreeuwel J
    Neth J Med; 1992 Aug; 41(1-2):71-3. PubMed ID: 1407243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drugs for inflammatory bowel disease.
    Treat Guidel Med Lett; 2012 Mar; 10(115):19-28. PubMed ID: 22361569
    [No Abstract]   [Full Text] [Related]  

  • 26. [Experiences with phase III studies in the area of gastroenterology].
    Kruis W
    Verh Dtsch Ges Inn Med; 1991; 97():503-6. PubMed ID: 1687301
    [No Abstract]   [Full Text] [Related]  

  • 27. [Salicylates in the treatment of Crohn disease].
    Mangiarotti R; Prantera C
    Ann Ital Chir; 1994; 65(3):279-81. PubMed ID: 7887577
    [No Abstract]   [Full Text] [Related]  

  • 28. 1989 Henry Baker lecture. Inflammatory bowel disease: back to the future.
    Sachar DB
    Am J Gastroenterol; 1990 Apr; 85(4):373-6. PubMed ID: 2327377
    [No Abstract]   [Full Text] [Related]  

  • 29. [Pharmacological bases of therapy with 5-ASA].
    Beltrán B; Martínez-Cuesta MA; Calatayud S; Hinojosa J; Esplugues JV
    Gastroenterol Hepatol; 1997; 20(6):322-34. PubMed ID: 9296850
    [No Abstract]   [Full Text] [Related]  

  • 30. [Aminosalicylates and steroids in the treatment ot chronic inflammatory bowel diseases--consensus paper of the Working Group for Chronic Inflammatory Bowel Diseases of the OGGH].
    Dejaco C; Haas T; Kirchgatterer A; Miehsler W; Wenzl H; Knoflach P; Petritsch W; Vogelsang H; Reinisch W; Tilg H
    Z Gastroenterol; 2006 Jun; 44(6):525-38; discussion 539. PubMed ID: 16773519
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease.
    Carrat F; Seksik P; Colombel JF; Peyrin-Biroulet L; Beaugerie L;
    Aliment Pharmacol Ther; 2017 Feb; 45(4):533-541. PubMed ID: 27995656
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of inflammatory bowel disease.
    Botoman VA; Bonner GF; Botoman DA
    Am Fam Physician; 1998 Jan; 57(1):57-68, 71-2. PubMed ID: 9447214
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunopharmacology of 5-aminosalicylic acid and of glucocorticoids in the therapy of inflammatory bowel disease.
    Nikolaus S; Fölscn U; Schreiber S
    Hepatogastroenterology; 2000; 47(31):71-82. PubMed ID: 10690587
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Update on the aminosalicylates: a promise fulfilled.
    Peppercorn MA
    Gastroenterology; 1988 Dec; 95(6):1677-80. PubMed ID: 2903113
    [No Abstract]   [Full Text] [Related]  

  • 35. Thorax as an extraintestinal target for inflammatory bowel disease.
    Akpınar EE; Gülhan M; Değertekin H; Ataoğlu Ö
    Tuberk Toraks; 2011; 59(3):312-5. PubMed ID: 22087529
    [No Abstract]   [Full Text] [Related]  

  • 36. Safety of high doses of mesalazine during pregnancy.
    Marteau P; Seksik P; Couve S; Jian R
    Am J Gastroenterol; 2005 Aug; 100(8):1897-8. PubMed ID: 16086733
    [No Abstract]   [Full Text] [Related]  

  • 37. 5-ASA therapy and renal function in inflammatory bowel disease.
    Siveke JT; Egert J; Sitter T; Schiemann U; Walcher P; Török HP; Glas J; Folwaczny C
    Am J Gastroenterol; 2005 Feb; 100(2):501. PubMed ID: 15667517
    [No Abstract]   [Full Text] [Related]  

  • 38. Review article: the effect of aminosalicylates and immunomodulation on cancer risk in inflammatory bowel disease.
    Stange EF
    Aliment Pharmacol Ther; 2006 Oct; 24 Suppl 3():64-7. PubMed ID: 16961748
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug-induced nephrotoxicity in inflammatory bowel disease.
    Oikonomou KA; Kapsoritakis AN; Stefanidis I; Potamianos SP
    Nephron Clin Pract; 2011; 119(2):c89-94; discussion c96. PubMed ID: 21677443
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Update on medical management of inflammatory bowel disease: ulcerative colitis.
    Hanauer SB
    Rev Gastroenterol Disord; 2001; 1(4):169-76. PubMed ID: 12120183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.